126 related articles for article (PubMed ID: 38810774)
1. Structural Adaptation of Secondary p53 Binding Sites on MDM2 and MDMX.
Higbee PS; Dayhoff GW; Anbanandam A; Varma S; Daughdrill G
J Mol Biol; 2024 Jul; 436(13):168626. PubMed ID: 38810774
[TBL] [Abstract][Full Text] [Related]
2. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
4. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
5. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
6. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
Zhao X; Xiong D; Luo S; Duan L
Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
[TBL] [Abstract][Full Text] [Related]
7. Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Sci Rep; 2020 Jul; 10(1):11449. PubMed ID: 32651397
[TBL] [Abstract][Full Text] [Related]
8. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.
Yadahalli S; Li J; Lane DP; Gosavi S; Verma CS
Sci Rep; 2017 Nov; 7(1):15600. PubMed ID: 29142290
[TBL] [Abstract][Full Text] [Related]
10. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
[TBL] [Abstract][Full Text] [Related]
11. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
12. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
Huang D; Qi Y; Song J; Zhang JZH
J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
[TBL] [Abstract][Full Text] [Related]
13. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
Chen J; Zhang D; Zhang Y; Li G
Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
[TBL] [Abstract][Full Text] [Related]
14. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
15. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
16. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
Lu SY; Jiang YJ; Zou JW; Wu TX
J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
[TBL] [Abstract][Full Text] [Related]
18. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
Cai X; Yuan ZM
J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
[TBL] [Abstract][Full Text] [Related]
19. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
20. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
